• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis gains further support from Innovate UK
Share
News, ProteaseTag®

ProAxsis gains further support from Innovate UK

July 24, 2017
-
Posted by Webmaster

Following its previous success in the BioMedical Catalyst competition, ProAxsis Limited (www.proaxsis.com) has now gained further support for its ProteaseTag® technology, via a project co-funded by the UK’s innovation agency, Innovate UK. The project, entitled “Development of technology to support the advance of new protease therapeutics”, has been awarded a grant in the Innovation in Health and Life Sciences Round 1 competition.

A number of pharmaceutical companies are currently developing inhibitors against protease targets, such as neutrophil elastase, as treatments of respiratory diseases including bronchiectasis, COPD and cystic fibrosis. ProAxsis has previously developed a laboratory-based immunoassay and a rapid point-of-care test for neutrophil elastase, utilising its ProteaseTag® technology, which such companies can benefit from. However, ProAxsis continues to seek to advance the sensitivity of its technology to maximise the range of biological samples it can be used with, and thereby improve the chances of success for these potentially important new therapeutics.

Speaking about the news, Dr David Ribeiro, CEO of ProAxsis, said: “Innovate UK programmes are always hugely competitive so we’re delighted that our project has been selected and are extremely grateful to Innovate UK for their support. The development of suitable companion diagnostic tests is an essential part of the drug development process.”

The project will commence in July 2017, and will be conducted at the company’s purpose-built laboratory facilities at Catalyst Inc., in Belfast.

Any queries concerning ProAxsis’ Immunoassays for measuring active neutrophil elastase and active plasmin, or any other aspects of the company’s proprietary ProteaseTag® technology, can be directed to info@proaxsis.com.

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University Belfast.

Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information, please visit www.innovateuk.gov.uk

July 24, 2017
No comments yet

Related News

Other posts that you should not miss.
News

ProAxsis releases new NEATstik® data at the Irish Thoracic Society Conference 2021

November 15, 2021
-
Posted by Jessica Robinson

Dr Darragh McCafferty, ProAxsis’ Head of Assay Development, will be presenting new data on the company’s ongoing …

Read More
November 15, 2021
Posted by Jessica Robinson
Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProteaseTag® Active Neutrophil Elastase Immunoassay used to predict future risk of exacerbation in bronchiectasis

December 23, 2016
-
Posted by Webmaster

In a significant new study, a team at the University of Dundee has shown for the first time that sputum …

Read More
December 23, 2016
Posted by Webmaster
Announcements, News

ProAxsis Limited appoints first distributor for DACH region

December 14, 2020
-
Posted by David Ribeiro

ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active proteases and other inflammatory …

Read More
December 14, 2020
Posted by David Ribeiro
← PREVIOUS POST
ProAxsis registers European CE Mark for first neutrophil elastase point-of-care test
NEXT POST →
ProAxsis’ Active Neutrophil Elastase Immunoassay highlighted in Stanford University trial

Leave a Comment

Your feedback is valuable for us. Your email will not be published.
Cancel Reply

Please wait...
Submit Comment

Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis gains further support from Innovate UK - ProAxsis